文献速递心血管MR

射血分数保留型心力衰竭患者的心肌纤维化与预后:12项队列研究的汇总分析

Myocardial fibrosis and prognosis in heart failure with preserved ejection fraction: a pooled analysis of 12 cohort studies.
PubMed 文献 · Eur Radiol · 2023-09-02

该汇总分析纳入12项队列研究共2787例射血分数保留型心力衰竭患者,中位随访31.2个月,心血管磁共振评估的较高心肌纤维化水平与主要不良心脏事件风险(HR=1.34,95%CI=1.14-1.57)及全因死亡风险(HR=1.74,95%CI=1.27-2.39)升高相关;基于晚期钆增强或细胞外容积定义纤维化时均观察到风险升高。

要点

  • 心血管磁共振评估的较高心肌纤维化负担可预测射血分数保留型心力衰竭患者的不良预后。
  • 纤维化水平较高与主要不良心脏事件风险升高(HR=1.34,95%CI=1.14-1.57)及全因死亡风险升高(HR=1.74,95%CI=1.27-2.39)相关。
  • 基于晚期钆增强或细胞外容积定义心肌纤维化时,均观察到结局风险升高。

核心结论

  • 心血管磁共振评估的较高心肌纤维化负担可预测射血分数保留型心力衰竭患者的不良预后,基于晚期钆增强或细胞外容积的评估可用于风险分层和指导进一步治疗。

研究设计与样本

  • 汇总分析纳入12项队列研究共2787例射血分数保留型心力衰竭患者,检索三个医学数据库截至2023年2月28日,心肌纤维化通过心血管磁共振指标(晚期钆增强或心肌细胞外容积)评估。

诊断标准与关键数值

  • 较高心肌纤维化水平与主要不良心脏事件风险升高相关(HR=1.34,95%CI=1.14-1.57)。
  • 较高心肌纤维化水平与全因死亡风险升高相关(HR=1.74,95%CI=1.27-2.39)。
  • 基于晚期钆增强或细胞外容积定义心肌纤维化时,均观察到结局风险升高。

临床应用与阅片要点

  • 基于心血管磁共振的晚期钆增强或细胞外容积评估可推荐用于射血分数保留型心力衰竭患者的风险分层和指导进一步治疗。
  • 临床实践和未来研究中应考虑将心血管磁共振检查纳入射血分数保留型心力衰竭患者的诊断和风险评估流程。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Heart failure with preserved ejection fraction (HFpEF) is a syndrome with significant clinical heterogeneity. Myocardial fibrosis has been considered a common pathological process in the development and progress of HFpEF. This study aimed to consolidate data on the prognostic effect of myocardial fibrosis, evaluated by cardiovascular magnetic resonance (CMR) imaging in patients with HFpEF.

METHODS: Three medical databases were searched for potentially related articles up to February 28, 2023. Cohort studies reporting associations between myocardial fibrosis and risk of all-cause mortality or composite major adverse cardiac outcomes (MACE) were included. Cardiac fibrosis was evaluated by CMR metrics, including late gadolinium enhancement (LGE) or myocardial extracellular volume (ECV). The hazard ratios (HRs) and 95% confidence intervals (CI) of the outcomes for higher myocardial fibrosis were calculated.

RESULTS: Twelve studies with 2787 patients with HFpEF were included for analysis. After a median follow-up duration of 31.2 months, a higher level of cardiac fibrosis was associated with a significant increase in the risk of MACE (HR = 1.34, 95% CI = 1.14-1.57) and all-cause mortality (HR = 1.74, 95% CI = 1.27-2.39), respectively. Furthermore, the increased risk of outcomes was both observed when cardiac fibrosis was defined according to LGE or ECV, respectively.

CONCLUSIONS: Higher burden of myocardial fibrosis evaluated by CMR can predict a poor prognosis in patients with HFpEF. Evaluation of LGE or ECV based on CMR could be recommended in these patients for risk stratification and guiding further treatment.

CLINICAL RELEVANCE STATEMENT: Inclusion of cardiovascular magnetic resonance examination in the diagnostic and risk-evaluation algorithms in patients with heart failure with preserved ejection fraction should be considered in clinical practice and future studies.

KEY POINTS: • Myocardial fibrosis is a common pathological process in heart failure with preserved ejection fraction. • A higher myocardial fibrosis burden on cardiac magnetic resonance predicts a poor prognosis in patients with heart failure with preserved ejection fraction. • Evaluation of myocardial fibrosis may be useful in patients with heart failure with preserved ejection fraction for risk stratification and treatment guidance.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Zhang X, Yang S, Hao S, et al. Myocardial fibrosis and prognosis in heart failure with preserved ejection fraction: a pooled analysis of 12 cohort studies. Eur Radiol. 2023. PMID: 37658896. doi:10.1007/s00330-023-10218-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。